Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice

Behavioural Pharmacology

Volumn 25, Issue 1, 2014, Pages 61-70

  Fish, Eric W ^a   Agoglia, Abigail E ^a,b   Krouse, Michael C ^a   Muller, R Grant ^a   Robinson, J Elliott ^a,b   Malanga, C J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

anticonvulsant; antiepileptic; drinking in the dark; intermittent access; mouse; SV2A

Indexed keywords

ETIRACETAM; SUCROSE; WATER;

ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ARTICLE; DRINKING BEHAVIOR; FOOD DRUG INTERACTION; MALE; MOUSE; NONHUMAN; SUGAR INTAKE;

ALCOHOL DRINKING; ANIMALS; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHOICE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING BEHAVIOR; ETHANOL; MALE; MICE; MICE, INBRED C57BL; PIRACETAM; SUCROSE; SWEETENING AGENTS;

EID: 84891848855     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000019     Document Type: Article

References (66)

1. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 173:32-40. (Pubitemid 38591144)
2. Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch L J (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 14:202-209.
3. Ballenger JC, Post RM (1978). Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 133:1-14. (Pubitemid 8371124)
4. Becker HC, Diaz-Granados JL, Weathersby RT (1997). Repeated ethanol withdrawal experience increases the severity and duration of subsequent withdrawal seizures in mice. Alcohol 14:319-326. (Pubitemid 27274736)
5. Becker HC (1998). Kindling in alcohol withdrawal. Alcohol Health Res World 22:25-33.
6. Becker HC (2013). Animal models of excessive alcohol consumption in rodents. Curr Top Behav Neurosci 13:355-377.
7. Benedetti MS, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E (2004). Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34:281-300. (Pubitemid 38478896)
8. Boyle AE, Segal R, Smith BR, Amit Z (1993). Bidirectional effects of gabaergic agonists and antagonists on maintenance of voluntary ethanol intake in rats. Pharmacol Biochem Behav 46:179-182.
9. Breese GR, Overstreet DH, Knapp DJ (2005). Conceptual framework for the etiology of alcoholism: a 'kindling'/stress hypothesis. Psychopharmacology (Berl) 178:367-380. (Pubitemid 40486977)
10. Breese GR, Sinha R, Heilig M (2011). Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther 129:149-171.
11. Doheny HC, Ratnaraj N,Whittington MA, Jefferys JG, Patsalos PN (1999). Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (UCB L059) in the rat. Epilepsy Res 34:161-168. (Pubitemid 29155487)
12. Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. (2012). A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res 36:1421-1430.
13. Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, Malanga CJ (2010). Alcohol, cocaine, and brain stimulation-reward in C57BL6/J and DBA2/J mice. Alcohol Clin Exp Res 34:81-89.
14. Gass JT, Olive MF (2008). Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75:218-265. (Pubitemid 350235390)
15. Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, et al. (2007). The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10:486-494. (Pubitemid 46567780)
16. Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E (1992). UCB L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222:193-203.
17. Gower AJ, Falter U, Lamberty Y (2003). Anxiolytic effects of the novel anti-epileptic drug levetiracetam in the elevated plus-maze test in the rat. Eur J Pharmacol 481:67-74. (Pubitemid 37456788)
18. Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, et al. (2010). Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev 35:334-344.
19. Holstein SE, Spanos M, Hodge CW (2011). Adolescent C57BL/6J mice show elevated alcohol intake, but reduced taste aversion, as compared to adult mice: a potential behavioral mechanism for binge drinking. Alcohol Clin Exp Res 35:1842-1851.
20. Hopf FW, Chang SJ, Sparta DR, Bowers MS, Bonci A (2010). Motivation for alcohol becomes resistant to quinine adulteration after 3 to 4 months of intermittent alcohol self-administration. Alcohol Clin Exp Res 34:1565-1573.
21. Hopf FW, Simms JA, Chang SJ, Seif T, Bartlett SE, Bonci A (2011). Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry 69:618-624.
22. Huang CC, Lo SW, Hsu KS (2001). Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748.
23. Hwa LS, Chu A, Levinson SA, Kayyali TM, DeBold JF, Miczek KA (2011). Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcohol Clin Exp Res 35:1938-1947.
24. Imperato A, Di Chiara G (1986). Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 239:219-228. (Pubitemid 16006360)
25. Johnson BA, Rosenthal N, Capece JA,Wiegand F, Mao L, Beyers K, et al. (2008). Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168:1188-1199. (Pubitemid 351831402)
26. Klitgaard H (2001). Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42 (Suppl 4):13-18. (Pubitemid 32802081)
27. Kokka N, Sapp DW, Taylor AM, Olsen RW (1993). The kindling model of alcohol dependence: similar persistent reduction in seizure threshold to pentylenetetrazol in animals receiving chronic ethanol or chronic pentylenetetrazol. Alcohol Clin Exp Res 17:525-531. (Pubitemid 23178433)
28. Krebs M, Leopold K, Richter C, Kienast T, Hinzpeter A, Heinz A, Schaefer M (2006). Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial. J Clin Psychopharmacol 26:347-349. (Pubitemid 43804637)
29. Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E (2006). Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 67:S28-S33. (Pubitemid 44967994)
30. Lamberty Y, Gower AJ, Klitgaard H (2002). The new antiepileptic drug levetiracetam normalises chlordiazepoxide withdrawal-induced anxiety in mice. Eur J Pharmacol 439:101-106. (Pubitemid 34286612)
31. Le Strat Y (2012). Levetiracetam in the treatment of alcohol dependence: toward the end of the story? Alcohol Clin Exp Res 36:1309-1310.
32. Linsenbardt DN, Boehm SL 2nd (2009). Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area. Neuroscience 164:424-434.
33. Lowery EG, Spanos M, Navarro M, Lyons AM, Hodge CW, Thiele TE (2010). CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis. Neuropsychopharmacology 35:1241-1252.
34. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101:9861-9866. (Pubitemid 38869327)
35. Mariani JJ, Levin FR (2008). Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. Am J Drug Alcohol Abuse 34:683-691.
36. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM (2011). A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 106:1227-1239.
37. Meehan AL, Yang X, Yuan LL, Rothman SM (2012). Levetiracetam has an activitydependent effect on inhibitory transmission. Epilepsia 53:469-476.
38. Melendez RI (2011). Intermittent (every-other-day) drinking induces rapid escalation of ethanol intake and preference in adolescent and adult C57BL/6J mice. Alcohol Clin Exp Res 35:652-658.
39. Mitchell JM, Grossman LE, Coker AR, Messing RO (2012). The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol 32:269-272.
40. Modesto-Lowe V, Huard J, Conrad C (2005). Alcohol withdrawal kindling: is there a role for anticonvulsants? Psychiatry 2:25-31.
41. Moore EM, Serio KM, Goldfarb KJ, Stepanovska S, Linsenbardt DN, Boehm SL 2nd (2007). GABAergic modulation of binge-like ethanol intake in C57BL/6J mice. Pharmacol Biochem Behav 88:105-113. (Pubitemid 47379828)
42. Mü ller CA, Schafer M, Schneider S, Heimann HM, Hinzpeter A, Volkmar K, et al. (2010). Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry 43:184-189.
43. Mü ller CA, Schafer M, Banas R, Heimann HM, Volkmar K, Forg A, et al. (2011). A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series. J Addict Med 5:153-156.
44. Nielsen CK, Simms JA, Pierson HB, Li R, Saini SK, Ananthan S, Bartlett SE (2008). A novel delta opioid receptor antagonist, SORI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavydrinking rats. Biol Psychiatry 64:974-981.
45. Nuutinen S, Lintunen M, Vanhanen J, Ojala T, Rozov S, Panula P (2011). Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology 36:2030-2040.
46. Ohno Y, Okumura T, Terada R, Ishihara S, Serikawa T, Sasa M (2012). Kindlingassociated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus. Neurosci Lett 510:93-98.
47. Osorio-Espinoza A, Alatorre A, Ramos-Jiménez J, Garduñ o-Torres B, Garcia-Ramirez M, Querejeta E, Arias-Montaño JA (2011). Pre-synaptic histamine H(3) receptors modulate glutamatergic transmission in rat globus pallidus. Neuroscience 176:20-31.
48. Perucca E, Johannessen SI (2003). The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disord 5 (Suppl 1):S17-S26. (Pubitemid 36818440)
49. Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC (2005). Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 84:53-63. (Pubitemid 40092065)
50. Richter C, Hinzpeter A, Schmidt F, Kienast T, Preuss UW, Plenge T, et al. (2010). Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. J Clin Psychopharmacol 30:720-725.
51. Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, et al. (2012). Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial. J Clin Psychopharmacol 32:558-562.
52. Robinson JE, Chen M, Stamatakis AM, Krouse MC, Howard EC, Faccidomo S, et al. (2013). Levetiracetam has opposite effects on alcohol-and cocaine-related behaviors in C57BL/6J mice. Neuropsychopharmacology 38:1322-1333.
53. Sarid-Segal O, Piechniczek-Buczek J, Knapp C, Afshar M, Devine E, Sickles L, et al. (2008). The effects of levetiracetam on alcohol consumption in alcoholdependent subjects: an open label study. Am J Drug Alcohol Abuse 34: 441-447. (Pubitemid 351913744)
54. Seevers MH (1968). Psychopharmacological elements of drug dependence. JAMA 206:1263-1266.
55. Shinn AK, Greenfield SF (2010). Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 71:634-648.
56. Simms JA, Nielsen CK, Li R, Bartlett SE (2013). Intermittent access ethanol consumption dysregulates CRF function in the hypothalamus and is attenuated by the CRF-R1 antagonist, CP-376395. Addict Biol [Epub ahead of print].
57. Sinnott RS, Phillips TJ, Finn DA (2002). Alteration of voluntary ethanol and saccharin consumption by the neurosteroid allopregnanolone in mice. Psychopharmacology (Berl) 162:438-447. (Pubitemid 35001908)
58. Sirsi D, Safdieh JE (2007). The safety of levetiracetam. Expert Opin Drug Saf 6:241-250. (Pubitemid 46767632)
59. Sparta DR, Sparrow AM, Lowery EG, Fee JR, Knapp DJ, Thiele TE (2008). Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol Clin Exp Res 32:259-265.
60. Sprow GM, Thiele TE (2012). The neurobiology of binge-like ethanol drinking: evidence from rodent models. Physiol Behav 106:325-331.
61. Tong X, Patsalos PN (2001). A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 133:867-874. (Pubitemid 32751796)
62. Ulrichsen J, Bech B, Allerup P, Hemmingsen R (1995). Diazepam prevents progression of kindled alcohol withdrawal behaviour. Psychopharmacology (Berl) 121:451-460.
63. Van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA (2009). Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50:422-433.
64. Williams-Hemby L, Porrino L J (1997). II. Functional consequences of intragastrically administered ethanol in rats as measured by the 2-[14C]deoxyglucose method: the contribution of dopamine. Alcohol Clin Exp Res 21:1581-1591.
65. Yang XF, Rothman SM (2009). Levetiracetam has a time-and stimulationdependent effect on synaptic transmission. Seizure 18:615-619.
66. Zalewska-Kaszubska J, Bajer B, Czarnecka E, DyrW, Gorska D (2011). Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study. Physiol Behav 102:538-541.